gbr-12935 dihydrochloride

GBR 12935 dihydrochloride (GBR 12935) can induce the increase of the extracellular levels of dopamine to basal levels.

GBR 12783 dihydrochloride (GBR12783 2HCl) is a specific, potent and selective dopamine uptake inhibitor. GBR 12783 dihydrochloride inhibits the [3H]dopamine uptake by rat and mice striatal synaptosomes with IC50s of 1.8 nM and 1.2 nM, respectively.GBR 12783 dihydrochloride can improve memory performance and increase hippocampal acetylcholine release in rats.

GBR-12935 is a piperazine derivative. It is an effective and selective dopamine reuptake inhibitor. GBR-12935 is now widely used in animal research into Parkinson's disease and the dopamine pathways in the brain.

GBR-12935 is a potent and selective dopamine reuptake inhibitor. It was originally developed in its 3H radiolabelled form for the purpose of mapping the distribution of dopaminergic neurons in the brain by selective labelling of dopamine transporter proteins. This has led to potential clinical uses in the diagnosis of Parkinson's disease, although selective radioligands such as Ioflupane (¹²³I) are now available for this application. GBR-12935 is now widely used in animal research into Parkinson's disease and the dopamine pathways in the brain. (Source: http://en.wikipedia.org/wiki/GBR-12935).

GBR 13069 dihydrochloride is a dopamine uptake inhibitor.